Summary of change from baseline to week 24 in van der Heijde-Sharp score (randomised patients)
| Placebo+MTX | Golimumab 2 mg/kg+MTX | |
|---|---|---|
| Randomised patients (n) | 197 | 395 |
| Change in total vdH-S score | ||
| Mean (SD) | 1.09±3.19 | 0.03±1.90 |
| Median (IQ range) | 0.00 (0.00, 1.49) | 0.00 (−0.50, 0.50) |
| p Value vs placebo+MTX | <0.001 | |
| Patients with screening CRP ≥1.5 mg/dL (n) | 163 | 326 |
| Mean (SD) | 1.10±3.21 | −0.03±1.78 |
| Median (IQ range) | 0.00 (0.00, 1.50) | 0.00 (−0.50, 0.50) |
| Patients with screening CRP <1.5 mg/dL (n) | 34 | 69 |
| Mean (SD) | 1.04±3.19 | 0.31±2.39 |
| Median (IQ range) | 0.00 (0.00, 0.50) | 0.00 (−0.50, 1.00) |
| Total hand vdH-S score | ||
| Mean (SD) | 0.66±2.11 | 0.01±1.56 |
| Median (IQ range) | 0.00 (0.00, 0.75) | 0.00 (−0.48, 0.50) |
| p Value vs placebo+MTX | <0.001 | |
| Total feet vdH-S score | ||
| Mean (SD) | 0.43±1.69 | 0.03±0.88 |
| Median (IQ range) | 0.00 (0.00, 0.00) | 0.00 (0.00, 0.00) |
| p Value vs placebo+MTX | 0.012 | |
| Change in Erosion score | ||
| Mean (SD) | 0.53±2.09 | −0.12±1.15 |
| Median (IQ range) | 0.00 (0.00, 0.50) | 0.00 (−0.50, 0.00) |
| p Value vs placebo+MTX | <0.001 | |
| Change in JSN score | ||
| Mean (SD) | 0.56±1.73 | 0.14±1.33 |
| Median | 0.00 (0.00, 0.50) | 0.00 (0.00, 0.00) |
| p Value vs placebo+MTX | 0.002 | |
CRP, C reactive protein; JSN, joint space narrowing; MTX, methotrexate; vdH-S, van der Heijde-Sharp.